Tribio Anti-PD-L1 & VEGF Bispecific Antibody (TBS10496)

Description

Description: Trbio Anti-PD-L1 & VEGF Bispecific Antibody is a research bispecific antibody that targets PD-L1 and VEGF to combine immune checkpoint blockade with anti-angiogenic activity. It is mainly used in cancer immunotherapy studies and preclinical tumor models to evaluate synergistic effects on T-cell activation and tumor vascular inhibition.

Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Species reactivity: Human

Host species: Human

Target: Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, CD274, Vascular endothelial growth factor A long form, L-VEGF, Vascular permeability factor, VPF, N-VEGF, VEGFA, VEGFA

Isotype: IgG-VHH

Accession/UniProt: Q9NZQ7 & P15692

Concentration: 3 mg/ml

Purity: >95%

Formulation: Liquid

Storage buffer: 0.01M PBS, pH 7.4

Purification: Protein A/G purified from cell culture supernatant.

Clonality: Monoclonal

Storage: Avoid repeated freeze-thaw cycles. -20°C for 12 months; -80°C for long-term storage.

Research use only.

Additional information